Lupin to present phase 1 data on LNP3693 at the ESMO Congress 2025: Our Bureau, Mumbai Monday, October 13, 2025, 16:30 Hrs [IST] Global pharma major Lupin Limited (Lupin) will pre ...
LNP3693 is an investigational parenteral STING agonist. The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in ...
MUMBAI, India and NAPLES, Fla. and BERLIN, Oct. 13, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback